Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

European Journal of Surgical Oncology

Volumn 34, Issue 5, 2008, Pages 547-552

  Mahteme, H ^a   von Heideman, A ^a   Grundmark, B ^a   Tholander, B ^b   Pahlman L ^a   Glimelius, B ^a,b   Larsson, R ^a   Graf, W ^a   Nygren, P ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytotoxic drug; In vitro; Intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MELPHALAN; MITOMYCIN C; OXALIPLATIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMATOUS PERITONITIS; CONCENTRATION RESPONSE; CROSS RESISTANCE; CULTURE MEDIUM; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CAMPTOTHECIN; CISPLATIN; CYTOTOXINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MELPHALAN; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; PERIOPERATIVE CARE; PERITONEAL NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 41949096959     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.05.002     Document Type: Article

References (20)

1. Mahteme H., Hansson J., Berglund A., et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 90 (2004) 403-407
2. Guner Z., Schmidt U., Dahlke M.H., Schlitt H.J., Klempnauer J., and Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis 20 (2005) 155-160
3. Gómez Portilla A., Barrios P., Rufian S., et al. Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 32 (2006) 628-631
4. Yan T.D., Black D., Savady R., and Sugarbaker P.H. Systematic review of the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24 (2006) 4011-4019
5. Verwaal V.J., van Ruth S., de Bree E., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21 (2003) 3737-3743
6. Glehen O., Mohamed F., and Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5 (2004) 219-228
7. Stephens A.D., Alderman R., Chang D., et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6 (1999) 790-796
8. Elias D., Raynard B., Bonnay M., and Pocard M. Heated intra-operative oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol 32 (2006) 607-613
9. González-Moreno S. Peritoneal surface oncology: a progress report. Eur J Surg Oncol 32 (2006) 593-596
10. Jaaback K., and Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (2006) CD005340
11. Armstrong D.K., Bundy B.B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
12. Sugarbaker P.H., Torres Mora J., Carmignani P., Stuart O.A., and Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. The Oncologist 10 (2005) 112-122
13. Katz M.H., and Barone R.M. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin North Am 12 (2003) 673-688
14. Elias D., Matsuhisa T., Sideris L., et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15 (2004) 1558-1565
15. Csoka K., Tholander B., Gerdin E., de la Torre M., Larsson R., and Nygren P. In vitro determination of cytotoxic drug-response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 72 (1997) 1008-1012
16. Fridborg H., Nygren P., and Larsson R. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs 6 (1995) 64-69
17. Larsson R., Kristensen J., Sandberg C., and Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50 (1992) 177-185
18. Nygren P., Fridborg H., Csoka K., et al. Detection of tumor specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56 (1994) 715-720
19. Nygren P., Hagberg H., Glimelius B., et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay (FMCA). Ann Oncol 5 (1994) 127-131
20. Villman K., Blomqvist C., Larsson R., and Nygren P. Predictive value of in vitro assessment of cytotoxic drug activity for response to chemotherapy in advanced breast cancer. Anticancer Drugs 16 (2005) 609-615